- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
- 10-K Annual report
- 10.40 Amended and Restated Director Compensation Policy
- 10.41 Agreement Between Inspire and Barry G. Pea
- 10.42 Employee Confidentiality, Invention Assignment and Non-compete Agreement
- 10.43 Transistion Agreement
- 10.44 Exclusive License Agreement
- 10.56 Form of Inspire Pharmaceuticals Employee Stock Option Agreement
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)/15D-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)/15D-14(A)
- 32.1 Certification of CEO Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 Certification of CFO Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Inspire Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2004, as filed with the Securities and Exchange Commission (the “Report”), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 11, 2005 | /s/ THOMAS R. STAAB, II | |
Thomas R. Staab, II Chief Financial Officer (principal financial officer) |